Compare · ANRO vs NMRA
ANRO vs NMRA
Side-by-side comparison of Alto Neuroscience Inc. (ANRO) and Neumora Therapeutics Inc. (NMRA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. ANRO focuses on Biotechnology: Pharmaceutical Preparations, while NMRA focuses on Biotechnology: Biological Products (No Diagnostic Substances).
- ANRO is the larger of the two at $999.2M, about 16.1x NMRA ($61.9M).
- ANRO has been more active in the news (6 items in the past 4 weeks vs 5 for NMRA).
- NMRA has more recent analyst coverage (23 ratings vs 13 for ANRO).
- Company
- Alto Neuroscience Inc.
- Neumora Therapeutics Inc.
- Price
- -
- -
- Market cap
- $999.2M
- $61.9M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NYSE
- NASDAQ
- IPO
- 2024
- 2023
- News (4w)
- 6
- 5
- Recent ratings
- 13
- 23
Latest ANRO
- SEC Form 144 filed by Alto Neuroscience Inc.
- SEC Form 10-Q filed by Alto Neuroscience Inc.
- Alto Neuroscience Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Alto Neuroscience Reports Third Quarter 2026 Financial Results and Recent Business Highlights
- Alto Neuroscience Announces New Employee Inducement Grants Under NYSE Rule 303A.08
- Alto Neuroscience Announces Participation in Upcoming Investor Conferences
- SEC Form 4 filed by Alto Neuroscience Inc.
- PRESIDENT AND CFO Smith Nicholas Conrad exercised 134,886 shares at a strike of $2.35 and sold $3,567,247 worth of shares (134,886 units at $26.45) as part of a pre-agreed trading plan (SEC Form 4)
- Alto Neuroscience Announces Participation in Upcoming Investor Conferences
- Alto Neuroscience Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
Latest NMRA
- Amendment: SEC Form SCHEDULE 13G/A filed by Neumora Therapeutics Inc.
- SEC Form 10-Q filed by Neumora Therapeutics Inc.
- Neumora Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Neumora Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
- Neumora Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- Officer Aurora Daljit Singh exercised 176,060 shares at a strike of $0.72 and sold $269,967 worth of shares (176,060 units at $1.53) (SEC Form 4)
- SEC Form 4 filed by Officer Berns Paul L
- SEC Form 4 filed by Officer Duncan Jason
- SEC Form 4 filed by Officer Milligan Michael Lee
- SEC Form 4 filed by President & CEO Pinto Joshua